Cargando…

Clinical and Virological Response to Convalescent Plasma in a Chronic Lymphocytic Leukemia Patient with COVID-19 Pneumonia

The burden of COVID-19 remains unchanged for immunocompromised patients who do not respond to vaccines. Unfortunately, Omicron sublineages are resistant to monoclonal antibodies authorized in Europe so far, and small chemical antivirals have contraindications and toxicities that have not been studie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Belcari, Giovanni, Conti, Alberto, Mazzoni, Alessandro, Lanza, Maria, Mazzetti, Paola, Focosi, Daniele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319583/ https://www.ncbi.nlm.nih.gov/pubmed/35888185 http://dx.doi.org/10.3390/life12071098

Ejemplares similares

Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor–recipient differences in concentration of neutralizing antibodies
por: Focosi, Daniele, et al.
Publicado: (2021)

Convalescent plasma in outpatients with COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

The art of the possible in approaching efficacy trials for COVID19 convalescent plasma
por: Focosi, Daniele, et al.
Publicado: (2021)

Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe
por: Focosi, Daniele, et al.
Publicado: (2022)

Convalescent Plasma Therapy for COVID-19: State of the Art
por: Focosi, Daniele, et al.
Publicado: (2020)

Convalescent plasma for COVID-19. TSUNAMI is not the final word
por: Franchini, Massimo, et al.
Publicado: (2022)

What is the optimal usage of coronavirus disease 2019 convalescent plasma donations?
por: Focosi, Daniele, et al.
Publicado: (2021)

Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews
por: Franchini, Massimo, et al.
Publicado: (2021)

WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients?
por: Franchini, Massimo, et al.
Publicado: (2023)

Convalescent plasma for COVID-19 in oncohematological patients: a call for revision of the European Conference on Infections in Leukemia-9 (ECIL-9) guidelines
por: Focosi, Daniele, et al.
Publicado: (2023)

On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy
por: Focosi, Daniele, et al.
Publicado: (2022)

Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency
por: Focosi, D., et al.
Publicado: (2021)

COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
por: Focosi, Daniele, et al.
Publicado: (2022)

Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J, et al.
Publicado: (2022)

Is a single COVID-19 vaccine dose enough in convalescents ?
por: Focosi, Daniele, et al.
Publicado: (2021)

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
por: Focosi, Daniele, et al.
Publicado: (2021)

SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma
por: Dulipsingh, Latha, et al.
Publicado: (2020)

Convalescent plasma in the management of COVID-19 pneumonia
por: Elbadawi, Ayman, et al.
Publicado: (2021)

Convalescent plasma to aid in recovery of COVID-19 pneumonia in a child with acute lymphoblastic leukemia
por: Shankar, Ravi, et al.
Publicado: (2021)

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J., et al.
Publicado: (2022)

Convalescent Plasma in a Patient with Protracted COVID-19 and Secondary Hypogammaglobulinemia Due to Chronic Lymphocytic Leukemia: Buying Time to Develop Immunity?
por: Hanssen, Jaap L. J., et al.
Publicado: (2021)

Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients—An Open-Label Phase II Clinical Trial
por: Grubovic Rastvorceva, Rada M., et al.
Publicado: (2022)

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis
por: Senefeld, Jonathon W., et al.
Publicado: (2023)

Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial
por: Menichetti, Francesco, et al.
Publicado: (2021)

COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors
por: Focosi, Daniele, et al.
Publicado: (2021)

Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients
por: Franchini, Massimo, et al.
Publicado: (2022)

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
por: Simonovich, Ventura A., et al.
Publicado: (2020)

Assessment of automated high-throughput serological assays for prediction of high-titer SARS-CoV-2 neutralizing antibody
por: Moscato, Giovanna, et al.
Publicado: (2021)

Convalescent Plasma Rescued a Severe COVID-19 Patient with Chronic Myeloid Leukemia Blast Crisis and Myelofibrosis
por: Zhang, Lu-Lu, et al.
Publicado: (2021)

Measurable residual disease in chronic lymphocytic leukemia
por: Benintende, Giulia, et al.
Publicado: (2023)

Convalescent plasma treatment for patients of 80 years and older with COVID-19 pneumonia
por: Romon, Iñigo, et al.
Publicado: (2021)

Blastoschizomyces capitatus pneumonia in a patient with untreated chronic lymphocytic leukemia
por: Trovato, Laura, et al.
Publicado: (2018)

Lethal human metavirus pneumonia in a patient with chronic lymphocytic leukemia
por: Rumpold, Holger
Publicado: (2021)

Klebsiella Pneumoniae Brain Abscess in a Patient With Chronic Lymphocytic Leukemia
por: Rajavel, Anisha, et al.
Publicado: (2022)

Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019
por: Bloch, Evan M, et al.
Publicado: (2023)

Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naïve BNT162b2 vaccine recipients
por: Azzi, Lorenzo, et al.
Publicado: (2021)

Earlier the better: convalescent plasma
por: Tobian, Aaron A.R., et al.
Publicado: (2020)

The resurgence of convalescent plasma therapy
por: The Lancet Haematology
Publicado: (2020)

COVID-19 convalescent plasma
por: Tobian, Aaron A. R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n9v1p4bs8iq3juuqn71gqb15a2